Clinical Trial Update: A Study to Investigate Safety and Effect of Sparsentan in Combination With SGLT2 Inhibition in Participants With IgAN [Phase 2]

View source ↗

Summary

A Phase 2 study evaluating the safety and effectiveness of sparsentan in combination with an SGLT2 inhibitor in immunoglobulin A nephropathy has completed and p…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Immunoglobulin Nephropathy

Drugs mentioned

• SGLT2 inhibitor
• Sparsentan (sparsentan)

Snippet

Sponsor: Travere Therapeutics, Inc. | Conditions: Immunoglobulin A Nephropathy | Phase 2 | Status: COMPLETED | Results posted: 2025-11-20